Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

Recruiting now · Phase 2

Conditions studied: Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer

In brief

The purpose of this research is to determine the expression of prostate specific membrane antigen (PSMA) in human epidermal growth factor receptor 2 (HER2)-negative, androgen receptor (AR)-positive metastatic breast cancer, and to determine its role in resistance to the anti-androgen, bicalutamide. The investigators hypothesize that PSMA expression will correlate with resistance to anti-androgen therapies, as has been documented in prostate cancer, and this can be used to select patients most likely to benefit from these therapies in future clinical trials. 15 people with HER2-negative, AR-positive metastatic breast cancer will be enrolled and be on study for about 3 days.

Key facts

Study ID
NCT04573231
Run by
University of Wisconsin, Madison
People needed
13
Starts
2021-05-24
Expected to finish
2026-08-01
Last updated by the study team
2026-08-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.